Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Evaluation of immunomodulatory activity of tenoxicam in mice

Fatima Nasim¹, Aqeel Javeed¹ , Muhammad Ashraf¹, Aamir Ghafoor²

¹Department of Pharmacology & Toxicology; ²University Diagnostic Lab, University of Veterinary and Animal Sciences, Lahore, Pakistan.

For correspondence:- Aqeel Javeed Email: aqeel.javeed@uvas.edu.pk Tel:+92429211449

Accepted: 11 April 2018 Published: 30 September 2018

Citation: Nasim F, Javeed A, Ashraf M, Ghafoor A. Evaluation of immunomodulatory activity of tenoxicam in mice. Trop J Pharm Res 2018; 17(9):1811-1816 doi: 10.4314/tjpr.v17i9.19

© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: The present study was conducted to evaluate the effect of tenoxicam on cellular and humoral immunity.

Methods: Tenoxicam (2.5 - 10mg/kg) was administered at three different doses to three groups of mice and the cellular immune responses were studied using delayed hypersensitivity response (DTH) and cyclophosphamide-induced neutropenia while the humoral immune response was evaluated using hemagglutination test and mice mortality ratio. Normal saline and cyclophosphamide were used as negative and positive controls, respectively.

Results: DTH assay resulted in a significant reduction in skin thickness (p < 0.05) for tenoxicam treated groups when compared to the negative control group at 24 h, 48 h and 72 h after administration of challenging dose of dinitrochlorobenzene (DNCB). Cyclophoshamide induced neutropenia showed a significant percentage reduction in total leukocyte count (TLC) and differential leukocyte count (DLC) i.e. lymphocytes and neutrophils (p< 0.05), but an increase in monocytes in all the treatment groups in the following order: 10 mg>5 mg >2.5 mg> negative control group. A dose dependent reduction response was observed (p<0.05) in haemagglutination assay (HA). In mice lethality test mortality ratios of 2.5 mg, 5 mg, 10 mg tenoxicam were 60 %, 80% and 100 %, respectively, compared to 20 % and 100 % for normal saline group and cyclophosphamide, respectively

Conclusion: The results suggest that tenoxicam suppresses both cellular and humoral immunity in mice.

Keywords: Tenoxicam, Cellular immunity, Humoral immunity